Answers are grounded in this paper and cite their sources.
Obesity is highly prevalent among women during the menopausal transition, yet current guidelines still offer limited direction on how to address it in this context. In this Letter, we emphasize the need to incorporate obesity assessment and treatment into menopause care. Obesity worsens vasomotor and genitourinary symptoms and alters the risk profile of menopausal hormone therapy, particularly increasing thromboembolic risk with oral formulations. A more integrated approach-combining hormone therapy with obesity management strategies-could improve metabolic outcomes, relieve symptoms, and lower long-term cardiovascular and oncologic risks. Future guidelines should explicitly address this overlap to support more individualized care for women in midlife.
No takes yet. Share an insight, caveat, or question.
Allgayer et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: